Generic guidance aimed at health coaches whose clients take GLP-1 medications, noting the drugs are becoming a bigger part of weight management.
Recap by typeshit. Post by Facebook on Facebook.
Fiscal.ai posted a chart comparing Lilly and Novo Nordisk and says Lilly is pulling ahead in the obesity drug market. Only the chart is shared, with no other detail.
Sam Stone mixed GLP-1 Daily Support powder into a smoothie daily and came away with stomach aches and doubts about what it does.
Dr Desmond Wai shares the Novo Nordisk news and notes the FDA cleared semaglutide for fatty liver disease in the US more than a year earlier.
A short personal check-in from a creator who tags her post with tirzepatide. No numbers or details beyond the update itself.
Heal and Clinic notes that semaglutide acts on GLP-1 alone while tirzepatide targets both GIP and GLP-1, and says no single choice suits everyone.
Day 1 of the metabolic medicine meeting covered prediabetes, newer GLP-1 drugs, bariatric surgery debates and where diabetes meets cancer.
Loading…